These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37806792)

  • 1. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
    Mainz JG; Lester K; Elnazir B; Williamson M; McKone E; Cox D; Linnane B; Zagoya C; Duckstein F; Barucha A; Davies JC; McNally P;
    J Cyst Fibros; 2024 May; 23(3):474-480. PubMed ID: 37806792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
    Mainz JG; Zagoya C; Polte L; Naehrlich L; Sasse L; Eickmeier O; Smaczny C; Barucha A; Bechinger L; Duckstein F; Kurzidim L; Eschenhagen P; Caley L; Peckham D; Schwarz C
    Front Pharmacol; 2022; 13():877118. PubMed ID: 35721187
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
    Mainz JG; Barucha A; Huang P; Bechinger L; Duckstein F; Polte L; Sadrieh P; Nährlich L; Eickmeier O; Van Dullemen S; Eschenhagen P; Schwarz C; Lüth S; Zagoya C; Graepler-Mainka U
    Front Pharmacol; 2023; 14():1167407. PubMed ID: 38026920
    [No Abstract]   [Full Text] [Related]  

  • 5. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.
    Duong JT; Pope CE; Hayden HS; Miller C; Salipante SJ; Rowe SM; Solomon GM; Nichols D; Hoffman LR; Narkewicz MR; Green N
    J Cyst Fibros; 2024 May; 23(3):490-498. PubMed ID: 38448281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
    Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
    Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
    Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
    Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
    Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 10. Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.
    De Vuyst R; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2024 Jul; 59(7):2051-2054. PubMed ID: 38629427
    [No Abstract]   [Full Text] [Related]  

  • 11. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.
    Testa I; Indolfi G; Brugha R; Verkade HJ; Terlizzi V
    J Cyst Fibros; 2024 May; 23(3):554-560. PubMed ID: 38614868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
    Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
    J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung clearance index (LCI
    Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
    Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
    Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS
    Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
    Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
    J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.
    Stastna N; Kunovsky L; Svoboda M; Pokojova E; Homola L; Mala M; Gracova Z; Jerabkova B; Skrickova J; Trna J
    Dig Dis; 2024; 42(4):361-368. PubMed ID: 38569478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
    Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
    J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 20. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.